

Amendments to the Claims:

Please amend claims 5, 13 and 19 as set forth below.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously Presented) A method of protecting neuronal cells from cell death in a subject having or at risk of having a stroke, comprising administering to the subject, a therapeutically effective amount of activated protein C (APC) in a bolus injection, thereby providing neuroprotection to the subject.
2. (Original) The method of claim 1, wherein the APC is administered intravenously.
3. (Cancelled)
4. (Previously Presented) The method of claim 1, wherein the APC is administered during the stroke or up to six hours before or after the stroke.
5. (Currently Amended) The method according to claim 1, wherein the method further comprises administering a therapeutically effective amount of protein S, wherein said therapeutically effective amount of protein S comprises about 2 mg/kg.
6. (Cancelled)
7. (Previously Presented) The method according to claim 1 wherein the method further comprises administering a therapeutically effective amount of a N-methyl-D-aspartate (NMDA) receptor antagonist or a calcium ion channel antagonist.
8. (Cancelled)
9. (Currently Amended) A method for reducing neurological inflammation in a subject having or at risk of having a stroke, comprising administering to the subject, a

therapeutically effective amount of activated protein C (APC) in a bolus injection, thereby reducing neurological inflammation in the subject.

10. (Original) The method of claim 9, wherein the APC is administered intravenously.

11. (Cancelled)

12. (Previously Presented) The method of claim 9, wherein the APC is administered during the stroke, or up to six hours before or after the stroke.

13. (Currently Amended) The method of claim 12, further comprising administering a therapeutically effective amount of Protein S, wherein said therapeutically effective amount of protein S comprises about 2 mg/kg.

14. (Cancelled)

15. (Currently Amended) A method for reducing neurological inflammation in a subject having or at risk of having inflammatory vascular disease comprising administering to the subject, a therapeutically effective amount of activated protein C (APC) in a bolus injection, thereby reducing neurological inflammation in the subject.

16. (Original) The method as in any of claims 1, 9 or 15, further comprising administering to the subject a therapeutically effective amount of one or more anticoagulant, anti-platelet or thrombolytic agent.

17. (Cancelled)

18. (Cancelled)

19. (Currently Amended) The method of claim 15, further comprising administering to the subject a therapeutically effective amount of Protein S, wherein said therapeutically effective amount of protein S comprises about 2 mg/kg.

In Re Application of:
Applicants Griffin and Zlokovic
Serial No: 09/777,484
Filed: February 5, 2001
Page 4

PATENT
Attorney Docket No.: SCRIP1200-1

20. (Cancelled)

21. (Cancelled)

22. (Previously Presented) The method of any of claims 1, 9, or 15 further comprising administering a continuous infusion of APC following the bolus injection.